Literature DB >> 34080771

Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1β drives amplified responses in primed astrocytes and neuronal network dysfunction.

Ana Belen Lopez-Rodriguez1, Edel Hennessy1, Carol L Murray1, Arshed Nazmi1, Hugh J Delaney1,2, Dáire Healy1, Steven G Fagan1, Michael Rooney1, Erika Stewart1, Anouchka Lewis1, Niamh de Barra1, Philip Scarry1, Louise Riggs-Miller1, Delphine Boche3, Mark O Cunningham2, Colm Cunningham1.   

Abstract

Neuroinflammation contributes to Alzheimer's disease (AD) progression. Secondary inflammatory insults trigger delirium and can accelerate cognitive decline. Individual cellular contributors to this vulnerability require elucidation. Using APP/PS1 mice and AD brain, we studied secondary inflammatory insults to investigate hypersensitive responses in microglia, astrocytes, neurons, and human brain tissue. The NLRP3 inflammasome was assembled surrounding amyloid beta, and microglia were primed, facilitating exaggerated interleukin-1β (IL-1β) responses to subsequent LPS stimulation. Astrocytes were primed to produce exaggerated chemokine responses to intrahippocampal IL-1β. Systemic LPS triggered microglial IL-1β, astrocytic chemokines, IL-6, and acute cognitive dysfunction, whereas IL-1β disrupted hippocampal gamma rhythm, all selectively in APP/PS1 mice. Brains from AD patients with infection showed elevated IL-1β and IL-6 levels. Therefore, amyloid leaves the brain vulnerable to secondary inflammation at microglial, astrocytic, neuronal, and cognitive levels, and infection amplifies neuroinflammatory cytokine synthesis in humans. Exacerbation of neuroinflammation to produce deleterious outcomes like delirium and accelerated disease progression merits careful investigation in humans.
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  APP/PS1; CCL2; IL-1β; astrocyte; chemokine; cytokine; delirium; dementia; gamma; memory; microglia; network dysfunction; neuroinflammation; primed; priming; vulnerability

Mesh:

Substances:

Year:  2021        PMID: 34080771      PMCID: PMC8874214          DOI: 10.1002/alz.12341

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  106 in total

1.  TLR2 hypersensitivity of astrocytes as functional consequence of previous inflammatory episodes.

Authors:  Anja Henn; Susanne Kirner; Marcel Leist
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

2.  Genomic analysis of reactive astrogliosis.

Authors:  Jennifer L Zamanian; Lijun Xu; Lynette C Foo; Navid Nouri; Lu Zhou; Rona G Giffard; Ben A Barres
Journal:  J Neurosci       Date:  2012-05-02       Impact factor: 6.167

3.  Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus.

Authors:  Ben Readhead; Jean-Vianney Haure-Mirande; Cory C Funk; Matthew A Richards; Paul Shannon; Vahram Haroutunian; Mary Sano; Winnie S Liang; Noam D Beckmann; Nathan D Price; Eric M Reiman; Eric E Schadt; Michelle E Ehrlich; Sam Gandy; Joel T Dudley
Journal:  Neuron       Date:  2018-06-21       Impact factor: 17.173

4.  Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation.

Authors:  M A Whittington; R D Traub; J G Jefferys
Journal:  Nature       Date:  1995-02-16       Impact factor: 49.962

5.  Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.

Authors:  Masashi Kitazawa; Salvatore Oddo; Tritia R Yamasaki; Kim N Green; Frank M LaFerla
Journal:  J Neurosci       Date:  2005-09-28       Impact factor: 6.167

6.  Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice.

Authors:  W C Benzing; J R Wujek; E K Ward; D Shaffer; K H Ashe; S G Younkin; K R Brunden
Journal:  Neurobiol Aging       Date:  1999 Nov-Dec       Impact factor: 4.673

7.  A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.

Authors:  Hadas Keren-Shaul; Amit Spinrad; Assaf Weiner; Orit Matcovitch-Natan; Raz Dvir-Szternfeld; Tyler K Ulland; Eyal David; Kuti Baruch; David Lara-Astaiso; Beata Toth; Shalev Itzkovitz; Marco Colonna; Michal Schwartz; Ido Amit
Journal:  Cell       Date:  2017-06-08       Impact factor: 41.582

Review 8.  Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease.

Authors:  W Sue T Griffin; Robert E Mrak
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

9.  Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction.

Authors:  Marie Orre; Willem Kamphuis; Lana M Osborn; Anne H P Jansen; Lieneke Kooijman; Koen Bossers; Elly M Hol
Journal:  Neurobiol Aging       Date:  2014-06-14       Impact factor: 4.673

10.  Is there a role for monocyte chemoattractant protein-1 in delirium? Novel observations in elderly hip fracture patients.

Authors:  Kjersti Skrede; Torgeir Bruun Wyller; Leiv Otto Watne; Ingebjørg Seljeflot; Vibeke Juliebø
Journal:  BMC Res Notes       Date:  2015-05-06
View more
  13 in total

Review 1.  A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials.

Authors:  Mitzi M Gonzales; Sudarshan Krishnamurthy; Valentina Garbarino; Ali S Daeihagh; Gregory J Gillispie; Gagan Deep; Suzanne Craft; Miranda E Orr
Journal:  Mech Ageing Dev       Date:  2021-10-21       Impact factor: 5.498

Review 2.  Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.

Authors:  Yuqing Liang; Shan Xie; Yanyun He; Manru Xu; Xi Qiao; Yue Zhu; Wenbin Wu
Journal:  Dis Markers       Date:  2022-01-19       Impact factor: 3.434

3.  Astrocytic C-X-C motif chemokine ligand-1 mediates β-amyloid-induced synaptotoxicity.

Authors:  Beatriz G Perez-Nievas; Louisa Johnson; Paula Beltran-Lobo; Martina M Hughes; Luciana Gammallieri; Francesca Tarsitano; Monika A Myszczynska; Irina Vazquez-Villasenor; Maria Jimenez-Sanchez; Claire Troakes; Stephen B Wharton; Laura Ferraiuolo; Wendy Noble
Journal:  J Neuroinflammation       Date:  2021-12-28       Impact factor: 8.322

4.  Low-grade peripheral inflammation affects brain pathology in the AppNL-G-Fmouse model of Alzheimer's disease.

Authors:  Lien Van Hoecke; Roosmarijn E Vandenbroucke; Junhua Xie; Nina Gorlé; Charysse Vandendriessche; Griet Van Imschoot; Elien Van Wonterghem; Caroline Van Cauwenberghe; Eef Parthoens; Evelien Van Hamme; Saskia Lippens
Journal:  Acta Neuropathol Commun       Date:  2021-10-07       Impact factor: 7.801

Review 5.  Cerebral dysfunctions caused by sepsis during ageing.

Authors:  Tatsuya Manabe; Michael T Heneka
Journal:  Nat Rev Immunol       Date:  2021-11-11       Impact factor: 108.555

6.  Risk of Dementia or Cognitive Impairment in Sepsis Survivals: A Systematic Review and Meta-Analysis.

Authors:  Siyuan Lei; Xuanlin Li; Hulei Zhao; Zhenzhen Feng; Liu Chun; Yang Xie; Jiansheng Li
Journal:  Front Aging Neurosci       Date:  2022-03-09       Impact factor: 5.750

Review 7.  Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer's Disease.

Authors:  Yuanxin Zhao; Buhan Liu; Jian Wang; Long Xu; Sihang Yu; Jiaying Fu; Xiaoyu Yan; Jing Su
Journal:  Biomedicines       Date:  2022-07-27

8.  Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19.

Authors:  Harmke B Duindam; Roy P C Kessels; Bram van den Borst; Peter Pickkers; Wilson F Abdo
Journal:  Brain Behav Immun Health       Date:  2022-09-18

Review 9.  Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation.

Authors:  Mateusz Watroba; Dariusz Szukiewicz
Journal:  Front Physiol       Date:  2022-08-15       Impact factor: 4.755

10.  Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals.

Authors:  Ya-Ru Zhang; Liu Yang; Hui-Fu Wang; Bang-Sheng Wu; Shu-Yi Huang; Wei Cheng; Jian-Feng Feng; Jin-Tai Yu
Journal:  Alzheimers Res Ther       Date:  2022-09-13       Impact factor: 8.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.